Just over five years ago the stock market began to react in earnest to news of the Covid pandemic.The sell-off was short and sharp, with a modest recovery from the lows in the spring followed by sharper gains in November 2020 after AstraZeneca (AZN) made a vaccine breakthrough.However, a large number of UK stocks are still trading below the levels they were at by the close of trading on 21 Februar

Hotter-than expected UK inflation for January, with headline CPI up 3% year-on-year versus the 2.8% expected, combined with a volatile geopolitical backdrop, means investors should be seeking ways to protect their income.Shares has long championed the unique advantage investment trusts have when it comes to paying regular and progressive dividends, since these funds are able to hold back up to 15%

Q4 sales and earnings beat consensusTotal dividend raised by 7% to $3.10Double-digit 2025 EPS growth targetShares in mega-cap pharmaceutical maker AstraZeneca (AZN) leapt to the top of the FTSE 100 leader board, gaining almost 5% after the company delivered a strong final quarter and despite what appeared to be a slightly below-market earnings outlook.Over the last 12 months, the shares have gaine

Stock prices in Europe opened in the green on Thursday, ahead of an expected interest rate cut by the Bank of England, with weekly US jobless claims figures also on the horizon.The FTSE 100 index added 67.85 points, 0.8%, at 8,691.14. The FTSE 250 rose 99.21 points, 0.5%, at 20,862.09. The AIM All-Share rose 1.51 points, 0.2%, at 717.17.The Cboe UK 100 was up 0.9% at 870.14, the Cboe UK 250 rose 0

First US approval for breast cancer drugTreatment reduces risk of death by 37%Eighth new medicine out of 20 set to deliver by 2030AstraZeneca (AZN) said the US FDA (Food and Drug Administration) has approved its cancer treatment Datroway to treat adult patients with breast cancer where surgery is not possible or where the cancer has spread through the body, who have already received standard of ca

Out of nowhere the market for weight loss drugs has become one of the most exciting investment themes in the last two years, rivalling investor enthusiasm for AI.There is good reason for the excitement. Rod Wong, managing partner at RTW Biotech Opportunities (RTW) fund describes the development of obesity drugs as the biggest ever financial opportunity in healthcare.That is because obesity is the

Analysts expect £78.5 billion in payouts£56.5 billion of buybacks this yearFTSE 100 up over 7% in 2024The latest AJ Bell Dividend Dashboard report shows FTSE 100 constituents are on course to pay £78.5 billion in ordinary dividends this year.That figure is almost flat on 2023 and well below the all-time high of £85.2 billion recorded in 2018, although analysts are penciling in a 6.5% increase

The FTSE 100 index closed up on Thursday, with AstraZeneca shares rising on US FDA approval of its Imfinzi treatment.Also on Thursday, UK Prime Minister Keir Starmer promised a 'relentless focus on delivering for working people' ahead of a major speech setting out targets to measure progress on his government's plans.AJ Bell's Danni Hewson noted: 'The prime minister today said that households will

AstraZeneca CEO buys 20,000 sharesTravis Perkins CEO buys 249, 218 sharesASOS director buys £430,135 sharesPascal Soriot, CEO of pharmaceutical firm AstraZeneca (AZN) has bought 20,000 shares at £102 for a total value of £2.04 million on 15 November.Soriot's purchase comes after the pharmaceutical giant delivered earnings ahead of consensus forecasts and raised its outlook on 14 November.Over t

Shares in pharmaceutical firm AstraZeneca (AZN) have fallen by around 16% over the past two months after recording an all-time high at the end of August.This reflects disappointing late-stage clinical trial results for the company's antibody cancer treatment Dato-DXd, being developed with Daiichi Sankyo (4568:TYO), but the shares lost around 5% on 30 October after the company said the president of

London's FTSE 100 closed lower on Tuesday, underperforming European peers, as index heavyweight AstraZeneca held back the large-cap benchmark.Eyes now turn stateside, hours before the closing of polls across the US - where Donald Trump and Kamala Harris lock horns in the presidential election.The FTSE 100 index closed down 11.85 points, or 0.1%, at 8,172.39. The FTSE 250 ended down 91.25 points, 0

European stocks were mixed on Wednesday morning, with the FTSE 100 trading resiliently, after China announced it will hold a fiscal policy-focused conference this weekend amid a backdrop of investor nerves for the Asian economy.The FTSE 100 index was up 38.24 points, 0.5%, at 8,228.85.London's powerhouse listings AstraZeneca, Shell and Unilever were all in the green in early trade, aiding the FTSE

Advanced breast cancer drug trial disappointsDrug unlikely to receive US approvalSeveral trials could yet revive hopesAnglo-Swedish pharmaceutical giant AstraZeneca (AZN) was on the back foot on Monday after reporting disappointing late-stage trial results for Dato-DXd, its precision advanced breast cancer experimental drug.The news sent the shares down 1.4% to £116.10, a new three month low and

AstraZeneca director buys £235,855 sharesComputacenter director buys 8,900 sharesEssentra non-executive director buys 70,000 sharesMichael Demare, non-executive chair of pharmaceutical giant AstraZeneca (AZN) has bought 2,000 shares at £117.93 for a total value of £235,855 on 13 September.Demare's move comes after the pharmaceutical giant's shares recently fell to a one-month low after the UK's

US regulatory approval for FasenraPositive results from late-stage trialsShares recover some lost groundAfter a string of disappointing clinical trial results which have weighed on AstraZeneca's (AZN) shares in the last month, the pharmaceutical firm said it has received US regulatory approval for Fasenra, its treatment for a rare disease which causes inflammation of the blood vessels.Investors we

As we write AI (artificial intelligence) chip champion Nvidia (NVDA:NASDAQ) has fallen more than 16% since reporting second quarter numbers. That's the equivalent of losing an entire Procter & Gamble (PG:NYSE) or two AstraZeneca's (AZN), the UK's largest listed company.To lose one AstraZeneca might be considered unfortunate, losing two is downright incompetence.Quips aside, more than $400 billion

Late-stage lung cancer trial disappointsTreatment was expected to be 'blockbuster'US regulatory approval now in doubtShares in pharmaceutical giant AstraZeneca (AZN), fell more than 5% to a one month low after the UK's largest quoted company released disappointing data from a late-stage clinical trial of its precision lung cancer drug Dato-DxD.The shares have been on a tear over the last six month

Blue chips traded lower at midday on Tuesday, pegged back by falls in several index heavyweights, in a mixed day for stocks in London.The FTSE 100 index traded down 43.48 points, 0.5%, at 8,227.36. The FTSE 250 was up 32.47 points, 0.2%, at 20,683.35, and the AIM All-Share was down 0.69 of a point, 0.1%, at 746.04.The Cboe UK 100 was down 0.4% at 823.76, the Cboe UK 250 rose 0.4% at 18,228.80, and

Investigation into chip designer's business practicesRecord $279 billion already wiped off market capExtra layer of uncertainty attached to investment caseA week after reporting another record quarter, Nvidia (NVDA:NASDAQ) is facing a fresh challenge. The chip designer is now firmly in the sights of US Department of Justice over complaints that it is violating antitrust laws.Investors are worried.

Stock prices in London opened mixed on Thursday while European counterparts were in the green, amid news that the UK economy flatlined monthly in June amid investor caution before the general election in July.The FTSE 100 index opened up 8.31 points, or 0.1%, at 8,289.36. The FTSE 250 was down 41.98 points, or 0.2%, at 20,910.54, and the AIM All-Share was down 0.87 points, or 0.1%, at 770.64.The C